Page 340 - Read Online

Shrestha et al. Hepatoma Res 2019;5:32 I http://dx.doi.org/10.20517/2394-5079.2019.24 Page 17 of 17

106. Funaki S, Shintani Y, Kawamura T, Kanzaki R, Minami M, et al. Chemotherapy enhances programmed cell death 1/ligand 1
expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer. Oncol Rep 2017;38:2277-84.
107. Wicklein D, Otto B, Suling A, Elies E, Lüers G, et al. CEACAM1 promotes melanoma metastasis and is involved in the regulation of
the EMT associated gene network in melanoma cells. Sci Rep 2018;8:11893.
108. Wang Y, Hu J, Ye W, Zhang X, Ju H, et al. EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human
salivary adenoid cystic carcinoma cells. Cell Cycle 2018;17:1457-70.
109. Ueno T, Tsuchikawa T, Hatanaka KC, Hatanaka Y, Mitsuhashi T, et al. Prognostic impact of programmed cell death ligand 1 (PD-L1)
expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. Oncotarget 2018;9:20034-47.
110. Liang J, Liu Z, Zou Z, Tang Y, Zhou C, et al. The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures
Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer. Sci Rep 2018;8:6570.
111. Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, et al. PD-L1 expression is regulated by both DNA methylation and NF-
kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 2018;7:e1423170.
112. Li CW, Lim SO, Xia W, Lee HH, Chan LC, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell
activity. Nat Commun 2016;7:12632.
113. Ihling C, Naughton B, Zhang Y, Rolfe PA, Frick-Krieger E, et al. Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates
in Hepatocellular Carcinoma. Front Med 2019;6:15.
114. Liakopoulou C, Kazazis C, Vallianou NG. Silimarin and Cancer. Anticancer Agents Med Chem 2018;18:1970-4.
115. Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, et al. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint
inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother 2018;67:1305-15.
116. Shali S, Yu J, Zhang X, Wang X, Jin Y, et al. Ecto-5’-nucleotidase (CD73) is a potential target of hepatocellular carcinoma. J Cell
Physiol 2019;234:10248-59.
117. Yuan L, Dong L, Yu G, Fan W, Zhang L, et al. Aberrant expression of B7-H4 may contribute to the development of hepatocellular
carcinoma. Mol Med Rep 2016;14:5015-24.
118. Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park)
2014;28 Suppl 3:30-8.
119. Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, et al. Patients Selection for Immunotherapy in Solid Tumors:
Overcome the Naïve Vision of a Single Biomarker. Biomed Res Int 2019;2019:9056417.
120. Sharma P. Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer J 2016;22:68-72.
121. Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, et al. Association of tumor PD-L1 expression and immune biomarkers with
clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin
Oncol 2013;31:3016.
122. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, et al. Mutational landscape determines sensitivity to PD-1 blockade in
non-small cell lung cancer. Science 2015;348:124-8.
123. Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, et al. α-PD-1 therapy elevates Treg/Th balance and increases tumor
cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J
Immunother Cancer 2019;7:62.
124. Zheng B, Ren T, Huang Y, Guo W. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting
STAT3. Biochem Biophys Res Commun 2018;495:1695-701.